Envista’s (NVST) “Hold” Rating Reiterated at Needham & Company LLC

Envista (NYSE:NVST)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a report issued on Tuesday,Benzinga reports.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company lifted their price objective on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Leerink Partners raised shares of Envista from an “underperform” rating to a “market perform” rating and lifted their target price for the company from $16.00 to $23.00 in a report on Thursday, October 31st. Robert W. Baird increased their price objective on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Finally, Mizuho initiated coverage on Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.21.

Envista Stock Up 2.4 %

NYSE:NVST opened at $21.36 on Tuesday. Envista has a 52 week low of $15.15 and a 52 week high of $23.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average is $20.15 and its two-hundred day moving average is $19.59. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of -3.29, a price-to-earnings-growth ratio of 1.27 and a beta of 1.34.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Research analysts anticipate that Envista will post 1 EPS for the current year.

Institutional Trading of Envista

A number of institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Envista during the third quarter worth about $31,000. Huntington National Bank increased its stake in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after purchasing an additional 1,638 shares during the last quarter. Blue Trust Inc. lifted its stake in Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after buying an additional 804 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after buying an additional 728 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.